Adjuvant chemotherapy in early uterine sarcoma.
Nine years' experience with early uterine sarcoma is reviewed. In addition to hysterectomy and radiotherapy, 34 patients received adjunctive chemotherapy; 67 patients received no adjunctive chemotherapy. Seventeen patients who received chemotherapy received combination vincristine, 1.5 mg/m2 weekly; actinomycin D, 0.5 mg intravenously on Days 1 to 5; and cyclophosphamide, 300 mg intravenously on Days 1 to 5. Seventeen other patients received adriamycin either alone at a dose of 50 mg/m2 BSA/month or in combination with vincristine and cyclophosphamide. Neither the probability of survival nor the disease-free interval was improved by the addition of adjuvant chemotherapy.
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003609:Dactinomycin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007044:Hysterectomy; D007890:Leiomyosarcoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D008875:Middle Aged; D011882:Radiotherapy, High-Energy; D012189:Retrospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D013997:Time Factors; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D003609:Dactinomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide